Last updated: 07/17/2024 16:54:36
To investigate the safety, pharmacodynamics and effect on allergic reactivity of the Toll-like receptor 7 (TLR7) agonist GSK2245035 in subjects with respiratory allergies
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A randomized, double blind, placebo-controlled study to investigate the safety, pharmacodynamics and effect on allergic reactivity of repeat intranasal administration of the TLR7 agonist GSK2245035 in subjects with respiratory allergies
Trial description: The purpose of this study is to examine the safety and effects on the immune system of treatment with GSK2245035 in subjects who suffer from nasal symptoms caused by an allergy to pollen or perennial allergen, with or without mild asthma. In addition, the effect of treatment with GSK2245035 on the body’s allergic response in test situations will be explored. Approximately 28 subjects will receive GSK2245035 (up to 14 subjects each receiving 80 nanograms [ng] GSK2245035 and up to 14 subjects each receiving 20 ng GSK2245035) and 14 subjects will receive the dummy drug (placebo) during the study. Assignment of a subject to GSK2245035 or placebo will be done by chance, like flipping a coin. Neither the subjects nor the clinic staff will know whether a subject is being dosed with GSK2245035 or placebo during the course of the study. The study will include (a) Screening phase where the eligibility of subjects for enrolment will be assessed (b) Treatment phase during which subjects will receive either 8 nasal sprays of GSK2245035 80 ng or a matching placebo once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in this study in 2014 will receive a reduced dose of 20 ng i.n. of GSK2245035 once weekly for eight administrations (c) Follow-up period where any GSK2245035 induced changes to the immune system and the effect of treatment on the body’s allergic response in test situations will be monitored. The maximum planned study duration for all subjects, including the screening, treatment and follow-up periods, is approximately 180 days.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: Up to 180 days
Number of participants with Cytokine Release Syndrome (CRS) Events
Timeframe: Up to 180 days
Change from Baseline in Body Temperature at the Indicated Time Points
Timeframe: Up to DV 8 ( i.e. 8 weeks)
Forced Expiratory Volume in 1 Second (FEV1) at Indicated Time Points
Timeframe: Screening and follow up visit 1 (7 days post DV 8 i.e 8 weeks)
Peak Expiratory Flow (PEF) at Indicated Time Points
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Total Protein assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Alkaline Phosphatase, Alanine Amino transferase, Aspartate Amino transferase and Gamma Glutamyl transferase assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Total Bilirubin, Creatinine, and Uric Acid assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Albumin, Calcium, Chloride, Carbon dioxide content/ Bicarbonate, Glucose, Potassium, Sodium, Urea/ BUN assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Basophil, Eosinophil, Lymphocyte, Monocyte, Total Neutrophil, Platelets, and White Blood Cell Count Values assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Erythrocyte Sedimentation Rate (ESR) assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Hemoglobin assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Mean Corpuscle Hemoglobin concentration assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Mean Corpuscle Hemoglobin assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Mean Corpuscle Volume assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Red Blood Cell count (RBC) and Reticulocytes assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Number of participants with abnormal Urinalysis Dipstick Results
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
C-Reactive protein assessment
Timeframe: Up to Follow-up visit 2 ( 21 days post 8 weeks dosing)
Number of participants with the indicated nasal examinations
Timeframe: Up to Follow-up visit 2 (21 days post 8 week s dosing)
Nasal Tolerability Symptoms as measured by a Visual Analogue Scale (VAS)
Timeframe: Up to DV 8 ( 8weeks)
Measurement of Toll like receptor 7 (TLR7)-induced Blood Pharmacodynamic (PD) Biomarkers
Timeframe: DV1 ( Week 1), DV8 (Week 8), follow up visit 1 and 2
Measurement of TLR7-induced Nasal PD Biomarkers
Timeframe: DV1 ( Week 1), DV8 (Week 8), follow up visit 1 and 2
Secondary outcomes:
Not applicable
Interventions:
Drug: GSK2245035
Drug: Placebo
Enrollment:
42
Observational study model:
Not applicable
Primary completion date:
2014-13-08
Time perspective:
Not applicable
Clinical publications:
Ellis AK, Tsitoura DC, Quint D, Powley W, Lee LA. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial. Clin Exp Allergy. 2017;47(9):1193-1203.
Medical condition
Asthma and Rhinitis
Product
GSK2245035
Collaborators
Not applicable
Study date(s)
March 2013 to August 2014
Type
Interventional
Phase
2
Participation criteria
Sex
Female & Male
Age
18 - 65 years
Accepts healthy volunteers
No
- Good general health, as determined by a responsible and experienced physician, based on a medical evaluation, including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
- Body weight >=45 kilograms (kg)
- CRITERIA BASED UPON MEDICAL HISTORIES
- History of immunological disorders or other diseases (including, but not limited to, malignancy, cardiovascular, gastro-intestinal, hepatic, renal, hematological, neurological, endocrine or pulmonary disease) that in the opinion of the investigator and GlaxoSmithKline (GSK) medical monitor may pose additional risk factors
Inclusion and exclusion criteria
Inclusion criteria:
- Good general health, as determined by a responsible and experienced physician, based on a medical evaluation, including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
- Body weight >=45 kilograms (kg)
- History of symptomatic pollen- or perennial allergen- driven allergic rhinitis with or without mild asthma (with a clear link between exposure to allergen and development of symptoms) for more than 2 years
- Positive skin allergy test (wheal >=3 mm[millimeters]) or serum allergen-specific Immunoglobulin E (IgE) (>=class 2) for perennial allergens and/or pollen allergens, relevant to the area of the research unit, within a year from the study start
- Positive screening nasal allergen challenge, defined by a Total nasal symptoms score (TNSS) response of >=5 (on a 12 point scale) and a decrease in Peak Nasal Inspiratory Flow (PNIF) of >30%
- Males and non-pregnant or non-lactating females between 18 and 65 years of age inclusive at the time of signing the consent form
- A female subject is eligible to participate if she is of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal, defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) >40 million international units (MIU)/mL and estradiol <40 picogram (pg)/mL (<147 picomoles (pmol)/liter (L) is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods with a failure rate of <1% if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks should elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method
- A female subject is eligible to participate if she is of child-bearing potential and has a negative early pregnancy test at screening, confirmed menses and/or a negative early pregnancy test within 10 days prior to the first dosing visit, a negative early pregnancy test before each dosing and agrees: to use one of the required contraception methods with a failure rate of <1% starting at least 2 weeks prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. The subject must agree to use contraception until four days after the last dosing; or has only same-sex partners, when this is her preferred and usual lifestyle
- Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods: Condom plus partner use of a required highly effective contraceptive (with a failure rate of <1%); or Abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. This criterion must be followed from the time of the first dose of study medication until four days after the last dosing
Exclusion criteria:
- CRITERIA BASED UPON MEDICAL HISTORIES
- History of immunological disorders or other diseases (including, but not limited to, malignancy, cardiovascular, gastro-intestinal, hepatic, renal, hematological, neurological, endocrine or pulmonary disease) that in the opinion of the investigator and GlaxoSmithKline (GSK) medical monitor may pose additional risk factors
- Nasal conditions that according to the opinion of the investigator may affect the outcome of the study, i.e. nasal septal perforation, nasal polyps, other nasal malformations or history of frequent nosebleeds
- Respiratory tract infection within 4 weeks prior to the first dosing
- History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >21 drinks for males or >12 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits
- History of drug or other allergy that, in the opinion of the investigator or GSK medical monitor, contraindicates participation in this study
- Serious asthma exacerbation requiring hospital visit and/ or treatment with oral steroids or high doses of inhaled steroids within 6 weeks prior to screening
- Subjects with a history of treatment with allergen-specific immunotherapy within the past 5 years are excluded. (Subjects who received incomplete treatment with allergen-specific immunotherapy more than 5 years ago may be included at the discretion of the investigator and GSK Medical Monitor)
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days prior to first dosing and throughout the treatment and follow-up period unless in the opinion of the investigator and/or GSK medical monitor the medication will not interfere with the study procedures or compromise subject safety. Acetaminophen is an exception and will be permitted at daily doses of up to 2 g from screening to follow-up. Approved contraceptives and pre-approved medications as specified in the protocol are also exempt
- Subjects using steroid treatment for allergic rhinitis and/or asthma may participate in the study if they can remain free of medication throughout the treatment and follow-up period starting from the following periods of time prior to screening: Nasal steroids-4 weeks, Oral steroids-12 weeks, Inhaled steroids-4 weeks
- Subjects using other medications for their allergic rhinitis and/or asthma on an as needed basis may participate in the study if they can abstain from: Xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates, leukotriene antagonists, 5-lipoxygenase inhibitors and long-acting inhaled beta-agonists from 1 week prior to screening and throughout the treatment and follow-up period; Nasal antihistamines-48 hours prior each visit; Oral antihistamines-76 hours prior each visit; Nasal decongestants-24 hours prior each visit; Oral decongestants-24 hours prior each visit; Short acting inhaled beta-agonists-48 hours prior each visit
- CRITERIA BASED UPON DIAGNOSTIC ASSESSMENTS
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- A positive test for Human Immunodeficiency Virus (HIV) antibody
- A positive screening or pre-dose drug/alcohol screen, with the following exceptions: (a) Subjects with positive results at the initial drug screening are excluded unless they have previously disclosed the use of a prescription drug that could cause a positive drug screen that according to the opinion of the Investigator and GSK Medical Monitor will not pose any safety risks to the subject and will not compromise the study (b) Subjects with a positive marijuana (THC) screen may be entered into the study at the investigator’s discretion but all pre-dose drug screens must be negative (c) Subjects with a positive alcohol screen may have this test repeated at a subsequent screening visit but all pre-dose alcohol screens must be negative.
- Pre-bronchodilator FEV1 <=70% of predicted at screening
- OTHER CRITERIA
- Participation in a clinical trial with receipt of an investigational product within 3 months prior to the first dosing day. Subjects may only participate in this study once even though the study is being conducted in two separate allergy seasons
- Exposure to more than four new chemical entities within 3 months prior to the first dosing day
- Donation of blood or blood products in excess of 500 mL within a 56-day period
- Subject is mentally or legally incapacitated
- Unwillingness or inability to follow the procedures outlined in the protocol
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2014-13-08
Actual study completion date
2014-13-08
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website